Adia Nutrition Announces Every Child in Autism Stem Cell Study Receives Umbilical Cord Blood-Derived Stem Cell Treatments Three Times - Open Nationwide and Worldwide with Participation Cost
Winter Park, Florida--(Newsfile Corp. - January 26, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), through its subsidiary Adia Med of Winter Park, LLC, today highlighted key details of its ongoing IRB-approved clinical study for children with Autism Spectrum Disorder (ASD), listed on ClinicalTrials.gov (NCT07304440). The trial ensures every participating child in Phase One or Phase Two receives umbilical cord blood-derived stem cell and exosome treatments (AdiaVita) three times, administered mont
Healthcare and Hospitals, Health
2026-01-26 10:00 AM EST | Adia Nutrition Inc.
Phio Pharmaceuticals Announces Participation in Third Annual DealFlow Discovery Conference
King of Prussia, Pennsylvania--(Newsfile Corp. - January 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026 at the Borgata Hotel in Atlantic City, NJ. Robert Bitterman, CEO and Chairman of th
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-01-26 8:15 AM EST | Phio Pharmaceuticals Corp.
FendX and Aquaox Enter into Collaboration Agreement to Pursue Innovation in Eco-Friendly Antimicrobial Agents
Vancouver, British Columbia--(Newsfile Corp. - January 22, 2026) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), an innovative surface protection company developing technology-based solutions to reduce the spread of harmful pathogens, is pleased to announce it has entered into a collaboration agreement (the "Agreement") dated January 20, 2026 with Aquaox LLC ("Aquaox"), a U.S. based manufacturer of environmentally
Technology, Healthcare and Hospitals, Health
2026-01-22 5:00 PM EST | FendX Technologies Inc.
LevelJump Enters into Cooperation Agreement with Concerned Shareholder; Announces Board Reconstitution
Toronto, Ontario--(Newsfile Corp. - January 20, 2026) - LevelJump Healthcare Corp. (TSXV: JUMP) (OTC Pink: JMPHF) ("LevelJump" or the "Company"), a leading provider of teleradiology and diagnostic imaging services, today announced that it has entered into a cooperation agreement (the "Agreement") with Frank Teti. Under the terms of the Agreement, LevelJump has agreed to a reconstitution of its Board of Directors (the "Board") to include new independent perspectives. Effective imm
Healthcare and Hospitals, Health
2026-01-20 4:00 PM EST | LevelJump Healthcare Corp.
Adia Nutrition Inc. Receives Notification from SEC: Form 10 to Become Effective on February 3, 2026
Winter Park, Florida--(Newsfile Corp. - January 20, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), a leader in regenerative medicine and personalized healthcare, today announced that it has been notified by the U.S. Securities and Exchange Commission (SEC) that its Form 10 registration statement will not be subject to further review. As a result, the Form 10 will automatically become effective 60 days after its original filing date, which is February 3, 2026. The Form 10, originally filed o
Healthcare and Hospitals, Health
2026-01-20 9:30 AM EST | Adia Nutrition Inc.
Phio Pharmaceuticals Announces Key Tumor Response Data from all Cohorts in Intratumoral PH-762 Dose Escalation Cutaneous Carcinoma Trial
King of Prussia, Pennsylvania--(Newsfile Corp. - January 20, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio an
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-01-20 9:30 AM EST | Phio Pharmaceuticals Corp.
BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC)
Vancouver, British Columbia--(Newsfile Corp. - January 20, 2026) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, in
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-01-20 8:00 AM EST | BioVaxys Technology Corp.
CORRECTION FROM SOURCE: LDIC Inc. Announces Senior Executive Appointments to Drive the Firm's Next Chapter of Strategic Growth
Toronto, Ontario--(Newsfile Corp. - January 19, 2026) - LDIC Inc. ("LDIC") announced a series of senior executive appointments that position the Firm for continued growth, enhanced client service, and long-term performance excel
Banking / Financial Services, Healthcare and Hospitals
2026-01-19 4:58 PM EST | Healthcare Special Opportunities Fund
Relief AI Assisting World Class Athletes in Mental Preparation For 2026 Olympic Winter Games
Toronto, Ontario--(Newsfile Corp. - January 19, 2026) - Relief AI Inc. (the "Company "or "Relief AI") (www.reliefai.ca), developer of the leading-edge workplace well-being platform naia, which identifies and assists professionals address early signs of workplace burnout, is proud to announce its sponsorship of World Cup Champion and Olympic hopeful Johannes "Hansi" Lochner, Germany's elite bobsleigh athlete. A
Technology, Healthcare and Hospitals, Health
2026-01-19 7:00 AM EST | Relief AI Inc.
NuGen Medical Devices Provides 2025 Year End Update on R&D and Strategic Progress
Toronto, Ontario--(Newsfile Corp. - January 16, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company"), a leader in needle-free subcutaneous drug-delivery technology, is providing a summary of key developments achieved during 2025 across its Research and Development programs, technical capabilities, clinical initiatives, and global commercial activities. 2025 Operational Highlights Research & Development Demonstrate
Healthcare and Hospitals, Pharmaceuticals, Health
2026-01-16 5:30 PM EST | NuGen Medical Devices Inc.
LDIC Inc. Announces Senior Executive Appointments to Drive the Firm's Next Chapter of Strategic Growth
Toronto, Ontario--(Newsfile Corp. - January 15, 2026) - LDIC Inc. ("LDIC") today announced a series of senior executive appointments that position the Firm for continued growth, enhanced client service, and long-term performance excellence. These appointments come as LDIC marks its 27th anniversary since its founding in 1998 and celebrates a second consecutive year of record-high assets under management. Genevieve Roch-Decter, CFA, currently President of LDIC, has been appointed Chief E
Banking / Financial Services, Healthcare and Hospitals
2026-01-15 11:00 PM EST | Healthcare Special Opportunities Fund
Adia Nutrition Promotes Emmanuela Derisbrun, APRN, FNP-C, to Provider Role Amid Growing Patient Demand and Launch of Autism IRB Study
Winter Park, Florida--(Newsfile Corp. - January 15, 2026) - Adia Nutrition Inc. (OTCQB: ADIA), through its medical division Adia Med specializing in advanced regenerative therapies, announces that Emmanuela Derisbrun, APRN, FNP-C, has transitioned from subcontractor to employed provider. This move supports rising patient volume and the launch of Adia Med's IRB-approved autism spectrum disorder regenerative study.
Healthcare and Hospitals, Health
2026-01-15 11:03 AM EST | Adia Nutrition Inc.
Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026
King of Prussia, Pennsylvania--(Newsfile Corp. - January 15, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical t
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-01-15 8:45 AM EST | Phio Pharmaceuticals Corp.
BioMark Diagnostics Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in Oncology
Vancouver, British Columbia--(Newsfile Corp. - January 15, 2026) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF) ("BioMark"), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to announce that its long-term investment in integrating artificial intelligence and machine learning into metabolomic profiling has achieved a major milestone. As the global healthcare investment community is focused on the transformative power of AI at the J.P. Mo
Technology, Biotechnology, Healthcare and Hospitals
2026-01-15 8:30 AM EST | BioMark Diagnostics, Inc.
Scryb Inc. Provides Early Warning Update on Holdings in Cybeats Technologies Corp.
Toronto, Ontario--(Newsfile Corp. - January 14, 2026) - Scryb Inc. (CSE: SCYB) (OTCQB: SCYRF) ("Scryb'' or the "Company"), is issuing this release to report information concerning its holdings in Cybeats Technologies Corp. (the "Issuer" or "Cybeats"). Scryb's total share ownership position of Cybeats is unchanged following all transactions outlined in this press release. Scryb outlines below that it accepted common shares in lieu of cash repayment from Cybeats Techno
Biotechnology, Healthcare and Hospitals, Health
2026-01-14 9:08 PM EST | Scryb Inc.
Adia Med Kicks Off Recruitment Today for Innovative Autism Stem Cell Study
Winter Park, Florida--(Newsfile Corp. - January 13, 2026) - ADIA Nutrition Inc. (OTCQB: ADIA), today announced that its subsidiary, Adia Med of Winter Park, LLC., has officially begun the recruitment process for a groundbreaking clinical study evaluating the potential benefits of stem cell therapy in children with Autism Spectrum Disorder (ASD). The 24-month randomized interventional study, officially titled "Adia MED of Winter Park LLC Autism Spectrum Disorder Research Study" and list
Healthcare and Hospitals, Health
2026-01-13 10:16 AM EST | Adia Nutrition Inc.
Ferring Pharmaceuticals and Theralase(R) Technologies Announce Clinical Development Agreement to Investigate Combination Therapy in Bladder Cancer
The collaborative clinical study will evaluate ADSTILADRIN® (nadofaragene firadenovec-vncg) in combination with the investigational drug Ruvidar® (TLD-1433) in patients with Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer carcinoma in-situ with or without papillary disease (±Ta/T1). Combination therapy aims to offer a comple
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-01-12 7:00 AM EST | Theralase Technologies Inc.
Cosmo Enters Scale Up Phase with 104M Revenue, 128M Cash, and Breakout AI and Dermatology Platforms
Ad hoc announcement pursuant to Art. 53 LR 2025 marks a key execution year in Cosmo’s Vision 2030, strengthening the Company’s foundations for scalable, innovation-driven growth across AI-enabled MedTech and pharma. Financial Highlights: High quality growth: €104 million revenue at guidance midpoint (€102 to €107 million) with recurring revenu
Healthcare and Hospitals, Health
2026-01-12 1:02 AM EST | Cosmo Pharmaceuticals N.V.
ADIA Nutrition Appoints Dawn Bell as Chief Revenue Officer to Accelerate Growth and Drive Success Across Physician Network
Winter Park, Florida--(Newsfile Corp. - January 8, 2026) - ADIA Nutrition, Inc. (OTCQB: ADIA), a rapidly growing leader in regenerative medicine, today announced the appointment of Dawn Bell as Chief Revenue Officer (CRO) through its subsidiary, ADIA Labs. Ms. Bell brings more than 15 years of proven expertise as a sales strategist in the medical device and pharmaceutical industries, with a strong history of driving growth and building successful partnerships.
Healthcare and Hospitals, Health
2026-01-08 8:30 AM EST | Adia Nutrition Inc.
BioVaxys Announces Phase 1 Clinical Study Results Advancing DPX(TM)-Formulated Products in Patients with Non-Muscle Invasive Bladder Cancer
Vancouver, British Columbia--(Newsfile Corp. - January 8, 2026) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB0) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, infectious disease, allergy, and other immune diseases based on its DPX™ antigen delivery and immune-educating technology platform, is pleased to announce highly promising results from a two-arm phase 1 clinical study of the safety and
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-01-08 8:00 AM EST | BioVaxys Technology Corp.